Dr. Wood is a 1992 graduate of Kansas State University College of Veterinary Medicine. Following graduation she completed an internship at the University of Georgia in small animal medicine and surgery. Dr. Wood finished her residency in medical oncology at Tufts University in 1996 and received her board certification in 1997. Following her residency she spent several years at the University of Minnesota followed by time at a private referral practice outside of Washington, D.C. She then moved back to Massachusetts to be nearer to family and friends and spent five years at the Angell Animal Medical Center in Boston followed by time working in New Hampshire and the Metrowest area. Desiring to spend less time commuting and more time teaching and with family, Dr. Wood is excited to be returning to Tufts in their well respected oncology department. In her free time Dr. Wood enjoys spending time with her family and their many pets. She enjoys downhill skiing, hiking and volunteering as a puppy raiser with a local service dog organization. Her special areas of interest include hematologic malignancies, clinical trials and working with industry to develop new cancer treatments for companion animals.
- Oncology Residency – Tufts University, 1996
- Internship – University of Georgia, 1993
- DVM – Kansas State University, 1992
- BS – University of Kansas 1982
Diplomate ACVIM - Oncology
- October 2013 - Angell AMC Newsletter, “Role of Diet and Nutrition in the Canine Cancer Patient”
- May 2012 - Angell AMC Newsletter “Canine Melanoma Vaccine”
- January 2011 - Massachusetts VMA Newsletter “Canine Mast Cell Tumors: More Changes on the Horizon”
- Moore, A. S., Imondi, A. R., de Souza, P. L. & Wood, C. A. (2003) Intravenous administration of 9-aminocamptothecin to dogs with lymphoma. Veterinary and Comparative Oncology 1 (2), 86-93.
- Payne, S. E., Rassnick, K. M., Northrup, N. C., Kristal, O., Chretin, J. D., Cotter, S. M., Kintzer, P., Frimberger, A. E., Morrison-Collister, K. E., Wood, C. A. & Moore, A. S. (2003) Treatment of vascular and soft-tissue sarcomas in dogs using an alternating protocol of ifosfamide and doxorubicin. Veterinary and Comparative Oncology 1 (4), 171-179.
- Moore AS, Cotter SM, Rand WM, Wood CA, Williams LE, London CA, Frimberger AE, L’Heureux DA. Evaluation of a discontinuous treatment protocol (VELCAP-S) for canine lymphoma. J Vet Intern Med. 2001 Jul-Aug; 15(4):348-54.
- Rassnick KM, Frimberger AE, Wood CA, Williams LE, Cotter SM, Moore AS. Evaluation of Ifosfamide for treatment of various canine neoplasms. J Vet Intern Med. 2000 May-Jun; 14(3):271-6.
- Moore AS, Wood CA, Engler SE, Bengtson AE. Radiation therapy for long term control of odontogenic tumors in cats. J Feline Med Surg. 2000 Mar; 2(1):57-60.
- Moore AS, London CA, Wood CA, Williams LE, Cotter SM, L’Heureux DA, Frimberger AE. Lomustine for the treatment of resistant lymphoma in dogs. J Vet Intern Med. 1999 Sep-Oct; 13(5):395-8.
- Zemann BI, Moore AS, Rand WM, Mason G, Ruslander DM, Frimberger AE,Wood CA, L’Heureux, Gliatto J, Cotter SM. A combination chemotherapy protocol (VELCAP-L) for dogs with lymphoma. J Vet Intern Med. 1998 Nov-Dec; 12(6): 465-70.
- Wood CA, Moore AS, Gliatto JM, Ablin LA, Berg RJ, Rand WM. Prognosis for dogs with Stage I or II splenic hemangiosarcoma treated by splenectomy alone: 32 cases (1991-1993). J Am Anim Hosp Assoc. 1998 Sep-Oct; 34(5):417-21.
General Research Interests
- Companion animal models of cancer
- Novel application of chemotherapies
- Clinical research trials
- Clinical Rotation in Small Animal Oncology